IYT 1.34IHF 0.95PTF 5.5872STN.TO -2.36BIP.UN.TO -0.42NFLX -0.94RKLB -4.72ASTS -2.39
Novo-Nordisk (NVO)

NYSE:NVO

Novo-Nordisk (NVO)

47.64
+0.23 (0.49%)
as of Jun 25, 2026, 8:00:00 pm Market Open.
265 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 25, 2026, 12:00 am

This summary was created by AI, based on 30 opinions in the last 12 months.

Novo Nordisk (NVO) has received mixed reviews from experts, with many expressing concerns about its competitive position against Eli Lilly (LLY) in the weight-loss and diabetes treatment market. Analysts note that LLY is outperforming NVO due to better clinical trial results and a more diversified product pipeline. The stock's technicals remain weak, with declining moving averages and uncertain earnings growth projections. Additionally, the potential challenges from generic competition and recent management changes have led to a lack of clarity regarding NVO's ability to capture market share. Despite these setbacks, some analysts see NVO as a long-term hold, given the growing demand in the diabetes and obesity markets, though caution is advised in the short term.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
BUY ON WEAKNESS

Novo-Nordisk(NVO)

Feb 07, 2020
International sales were up 11% and US at 1% due to pricing issues there. They are picking up market shares which gives them pricing power and allows them to go into India and China to earn higher margins. Getting out of the US is important for them. Once you get a moat around their product, the oral insulin pill and weight loss, it's smooth sailing. He's owned this since 1995. There are periods they struggle but over time, it's a gift that keeps giving. With the number of diabetics growing around the world, they will have good demand for its products. Right now, he would pause but he would have it in your portfolio.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$63.25

Stock price when the opinion was issued

$47.64

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Novo-Nordisk(NVO)

Jan 17, 2020
They have good exposure to the diabetes market, though less specialized growth in the next 10 years. They don't own it because their options are not liquid enough.
Photo of Paul MacDonaldPaul MacDonald
No
Unlock Rating
$61.31

Stock price when the opinion was issued

$47.64

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Jan 13, 2020
All pharma companies face pricing pressure in a US election year, because US candidates take shots at drug pricing. Also pharma companies need to keep putting new, successful drugs. NN succeeds in putting out new diabetes drugs (they lead this product segment globally).
Photo of Brett Girard, CPA, CA, CFABrett Girard, CPA, CA, CFA
Owned
Unlock Rating
$58.97

Stock price when the opinion was issued

$47.64

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Novo-Nordisk(NVO)

Dec 02, 2019
He has avoided it because insulin and products to replace it have had a lot of price increases and he fears they will be looked at by politicians. It is a very defensive issue and should do better when the economy slows.
Photo of David FingoldDavid Fingold
No
Unlock Rating
$56.02

Stock price when the opinion was issued

$47.64

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Nov 29, 2019
FDA approval for a tablet diabetes drug. China and India will have a growing market for this as well. The trend will help the bottom line and profitability. He's owned it since 1997, and though it hasn't done much in the last 5 years, it is picking up. They are also completely off the grid and is very environmental. (Analysts’ price target is $62.73)
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$56.15

Stock price when the opinion was issued

$47.64

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Novo-Nordisk(NVO)

Nov 05, 2019

The pharma sector. Any picks? Pharma's problem is the US election cycle when candidates always bash big pharma. But these stocks are not expensive now, like JNJ which boasts 3 divisions (consumer, medical devices and pharma); and Novo Nordisk, which offers a diabetes pill and obesity pill. Buy a small position now as well as when they pull back during the election campaign, and certainly after the election. NVO increases its dividend perennially. The Dems and Republicans are equally critical of pharma.

Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$56.46

Stock price when the opinion was issued

$47.64

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Sep 26, 2019
Their business is in hemophilia and diabetes (450 million have it globally and the number will rise). They make an obesity drug (a pill, that's showing growth) and sell the most insulin in the world. (Analysts’ price target is $56.45)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$52.19

Stock price when the opinion was issued

$47.64

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Aug 15, 2019
Big franchise is in diabetes. Explosive, secular growth in diabetes, and NVO is the largest producer of insulin in the world. Plus biopharma business. Yield is 1.77%. (Analysts’ price target is $54.45)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$50.74

Stock price when the opinion was issued

$47.64

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Aug 02, 2019
Over the next 25 years, type 2 diabetes will grow 55% led by India and China. Demand will be there. Novo needs to go and get this market. Starting to show better revenues and operating margins. They also have a new drug that is not just for diabetes but for weight loss.
Photo of David DriscollDavid DriscollUnlock Rating
$48.59

Stock price when the opinion was issued

$47.64

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Novo-Nordisk(NVO)

Jun 21, 2019
About to come out with a pill instead of injections. Stock has popped recently. Type 2 diabetics are going to increase 50% in the next 2 years, mainly in India and China. Margins are being squeezed. Have to work harder to get sales. Likes what they're doing. Leaders in the industry.
Photo of David DriscollDavid DriscollUnlock Rating
$50.84

Stock price when the opinion was issued

$47.64

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Apr 24, 2019
The play is the growth in diabetes -- 11% per year. More drugs and medications will be required and this company has the best market share in the space. As this is a global issue, they worldwide coverage is a great advantage. Yield 3.2% (Analysts’ price target is $53.45)
Photo of Kash PashootanKash Pashootan
Owned
Unlock Rating
$48.37

Stock price when the opinion was issued

$47.64

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Novo-Nordisk(NVO)

Feb 15, 2019
The company understands that diabetes is growing in China and India. They've been raising market share there. International operations grew by 7%. Oral pills instead of insulin shots are coming out shortly. Increased dividend, a bit below average. Oral pills, if positive, could easily be a 1-5B blockbuster.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$49.76

Stock price when the opinion was issued

$47.64

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Dec 13, 2018
Given that markets will be lack luster he is looking for defensive names. They are focused on the diabetes space. The disease is growing at double digit rates. With their economies of scale, their profit margin is higher than their competitors. The most significant growth in diabetes is in emerging markets where they pay for the drugs themselves. They have to be able to reduce their prices in these markets. (Analysts’ price target is $49.60)
Photo of Kash PashootanKash Pashootan
Owned
Unlock Rating
$46.77

Stock price when the opinion was issued

$47.64

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Nov 08, 2018
Biggest growth is on diabetes. Market leader. The numbers were a little soft on the last report. Structural growth story. (Analysts’ price target is $45.85)
Photo of Darren SissonsDarren SissonsUnlock Rating
$44.67

Stock price when the opinion was issued

$47.64

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Novo-Nordisk(NVO)

Nov 02, 2018

(A Top Pick Oct 04/17, Down 7%) Has owned this for 22 years. #1 insulin maker in the world. Just came out with a drug for weight loss. There'll be a 54% increase in diabetes in 12 years. They and Merck had the best revenue growth. Stock fell a little because a competitor got FDA approval for a similar insulin. They are selling more outside the U.S. and need to sell more to China and India. Then, the street will favour them again.

Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$43.72

Stock price when the opinion was issued

$47.64

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 121 to 135 of 203 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MNS.TO 1.29$45.39
MPWR 3.35$1438.3
MSFT -12.63$352.83
DAL 1.46$92.11
OTEX.TO 0.18$30.37

Today's Top Picks

IYT 1.34$86.64
IHF 0.95$54.45
PTF 5.587$132.24
STN.TO -2.36$96.32
BIP.UN.T… -0.42$51.62

Popular Articles

Latest Sell Signals

NVO 0.23$47.64
TRP.TO 0.93$99.6
RY.TO 1.09$289.12
TD.TO 1.61$170.9
ATD.TO -0.19$93.57

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Greg Newman

Greg Newman

Scotia Wealth Management

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically